$DD

DuPont (DD) Q2 2026 Earnings Call Transcript

DuPont (DD) reported Q2 2026 net sales of $1.8 billion, up 4% year over year, with organic sales growth of 4%. Operating EBITDA was $448 million, up 5.9%, and operating EBITDA margin rose to 24.6%. Adjusted EPS was $1.88, up 48%. The company raised full-year operating EBITDA guidance and plans a $250 million share repurchase program.

Original reporting
Published Aug 11, 2026, 5:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 5:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
DuPont (DD) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$DDBullishMed
01

Why it matters

Traders can update forward estimates using the raised EBITDA and EPS ranges, monitor the stated margin headwind path (30 bps in Q2, 50 bps in 2H), and track whether free cash flow conversion approaches the company’s near-100% target.

02

Market read

Raised guidance and a planned buyback are actionable for near-term positioning, while oil and gas inflation and regional water weakness remain key downside risks.

03

What to watch

Reverse stock split and sector reclassification can affect per-share optics and index flows, while the AI-enabled sales win rate is garment-specific and may not translate cleanly to the core industrial segments.

Relevance 8/10Novelty 8/10Timing: post-call, for positioning ahead of Q3 2026 and the next earnings cycle

Background

DuPont reported Q2 2026 results and provided updated full-year guidance during its earnings call transcript.

Company-level read

Ticker impact

$DDBullishMedium confidence
Context

DuPont raised full-year operating EBITDA guidance to $1.75B-$1.77B and adjusted EPS to $7.17-$7.32, citing currency and margin drivers.

Expected impact

Bias modestly positive for the next few sessions as traders reprice forward earnings and capital return, with sensitivity to any follow-up on inflation and working-capital conversion.

Evidence & confidence

The article provides specific, time-relevant guidance ranges and capital allocation details, but it is a transcript recap without explicit consensus comparison or new post-call market reaction.

Market effects

Signals continued demand strength in healthcare, aerospace, and semiconductor-adjacent ultra-pure water, which can support sentiment for industrial chemicals and specialty materials peers.

Middle East water weakness is cited as a drag, implying regional demand variability that could affect industrial water and purification supply chains.

Stronger U.S. dollar reduces currency benefit in guidance, highlighting FX sensitivity for multinational industrials.

Counterpoint

The margin outlook is still constrained by oil and gas inflation, and the large EPS increase may be partly driven by interest expense and working-capital assumptions that could disappoint later.

Key entities

  • DuPont de Nemours, Inc.

    Reported Q2 2026 results, raised full-year guidance, and announced a $250M share repurchase program for Q3 2026.

  • Lori Koch

    CEO who discussed water segment performance, AI scaling, and a direct lithium extraction solution.

  • Antonella Franzen

    CFO who highlighted margin headwinds from oil and gas inflation and free cash flow conversion expectations.

Related articles

$DDMed

DoubleDragon off to roaring start in H1

DoubleDragon Corp. reported H1 core net income up 162% to PHP 2.41 billion and revenues up 23% to PHP 8.55 billion, citing faster core revenue growth as it shifts from fair value gains to recurring operating income. It plans multiple mall, warehouse, and Hotel101 openings in H2 and a SGD 300 million REIT vehicle for Hotel101 projects.

$DDMed

Bonta accuses DuPont of corporate shell game to dodge PFAS cleanup in California

California Attorney General Rob Bonta filed an amended complaint alleging DuPont and related spin-offs used corporate restructurings to shift PFAS cleanup liabilities and keep assets out of reach. The filing targets New DuPont, Corteva, Chemours and Qnity Electronics, citing a 2015 Chemours spin-off, a $4 billion PFAS liability cap, and alleged insurance asset transfers. The case remains active in U.S. District Court.

$DDMed

California alleges DuPont used spin-off companies to avoid PFAS liability

California Attorney General Rob Bonta alleges in a federal filing that DuPont and three spin-offs used memorandums of understanding to shift most PFAS liabilities onto Chemours while limiting exposure for Corteva, New DuPont and Qnity. Bonta cites possible fraudulent transfer law violations. DuPont disputes; a prior New Jersey case settled for $2 billion.

$DDMedAI 8/10

New Jersey secures up to $2.5 billion from DuPont, 3M for PFAS cleanup

New Jersey will receive up to $2.5 billion from settlements with DuPont and 3M over PFAS environmental damages, according to The Philadelphia Inquirer. Judge Renée Marie Bumb approved agreements ending a case filed in 2019. 3M to pay $400m-$450m; DuPont-related entities $875m over 25 years, plus $1.2b remediation commitments.

$DDMedAI 8/10

Federal Court Approves $2.5 Billion New Jersey Settlement With DuPont, 3M Over ‘Forever Chemicals’

A federal court approved New Jersey’s $2.5 billion settlement with DuPont and 3M over PFAS (“forever chemicals”) contamination, state officials said. The deal resolves New Jersey suits filed in 2019 against DuPont and a separate case against 3M. Up to $365 million will fund site restoration near four locations. Payments are expected annually for 25 years.

$DDMedAI 8/10

New Jersey Judge Approves $2.5 Billion PFAS Settlements With DuPont and 3M

A New Jersey federal judge approved PFAS settlements totaling over $2.5 billion with DuPont, Chemours, Corteva and 3M, Reuters reported. The deals require cleanup of four former sites and compensation for natural-resource damages, including a $1.2 billion restoration fund. DuPont, Chemours and Corteva pay $875 million over 25 years; 3M pays $400-$450 million, plus a $475 million reserve.